Xbrane's first sales in 2017 will be of Spherotide: the first generic formulation of the prostate cancer therapy triptorelin (cancer sales about $380m). A SEK7m order is ready for shipment to Iran, once authorised. A Chinese deal worth SEK17m upfront, $8m total, may be signed in Q117. European partnering and launches are possible from 2019 after clinical trials. Xbrane (or a partner) may sell Xlucane, its low-cost biosimilar of Lucentis (2015 sales $3.6bn), in the US after 2021 and from 2022 in Europe.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs